AbCellera Biologics Inc.
HealthcareNASDAQ:ABCL · NASDAQ Global Select
-$0.03 today
Vol 2.94M · Avg 6.25M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$79.2M of revenue converted into -$144.0M of net income for the selected period. Gross margin is 69.6% and net margin is -345.0%, showing how much revenue survives after costs and taxes. EPS is $-0.48, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $75.1M +160.6% | $28.8M -24.2% | $38.0M -92.2% | $485.4M +29.4% | $375.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $28.8M | $0 | $0 -100.0% | $66.4M +46.0% | $45.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $46.3M +60.6% | $28.8M -24.2% | $38.0M -90.9% | $419.0M +27.1% | $329.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 61.6% -38.4pp | 100.0% +0.0pp | 100.0% +13.7pp | 86.3% -1.6pp | 87.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $186.8M +11.7% | $167.3M -4.8% | $175.7M +62.8% | $107.9M +73.8% | $62.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $76.6M -10.4% | $85.5M +13.7% | $75.2M +12.6% | $66.8M +36.9% | $48.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $263.4M -23.3% | $343.6M +24.8% | $275.2M +35.9% | $202.5M +61.6% | $125.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $28.8M -70.3% | $97.0M +214.0% | $30.9M -6.7% | $33.1M +91.9% | $17.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$148.8M +27.1% | -$204.1M -6.2% | -$192.2M -173.9% | $260.2M +8.8% | $239.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -198.0% +510.0pp | -708.0% -202.7pp | -505.3% -558.9pp | 53.6% -10.1pp | 63.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$217.1M +31.0% | -$314.8M -32.7% | -$237.2M -209.6% | $216.5M +5.9% | $204.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -289.0% +802.7pp | -1091.7% -467.9pp | -623.8% -668.4pp | 44.6% -9.9pp | 54.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $28.3M -26.4% | $38.5M -8.9% | $42.2M +162.7% | $16.1M +382.9% | $3.3M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 -100.0% | $4.0M -22.6% | $5.2M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $39.5M -65.5% | $114.4M +81.0% | $63.2M +179.7% | $22.6M +53.3% | $14.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$177.6M +11.4% | -$200.4M -15.2% | -$174.0M -172.8% | $239.1M +9.1% | $219.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -236.4% +458.6pp | -695.0% -237.3pp | -457.7% -506.9pp | 49.3% -9.2pp | 58.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$31.2M +16.9% | -$37.5M -35.9% | -$27.6M -134.3% | $80.6M +22.7% | $65.7M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$146.4M +10.1% | -$162.9M -11.2% | -$146.4M -192.4% | $158.5M +3.3% | $153.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | -194.9% +369.9pp | -564.8% -179.8pp | -385.0% -417.7pp | 32.7% -8.2pp | 40.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +10.9% | -$1 -7.8% | -$1 -191.1% | $1 +0.0% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +10.9% | -$1 -7.8% | -$1 -202.0% | $1 +4.2% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $298.7M +1.5% | $294.3M +1.8% | $289.2M +1.4% | $285.1M +3.4% | $275.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $298.7M +1.5% | $294.3M +1.8% | $289.2M -8.2% | $314.8M -1.1% | $318.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.62B
Biohaven Ltd.
NYSE:BHVN
$1.19B
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
$1.17B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ABCL generate?
AbCellera Biologics Inc. (ABCL) reported $75.13M of revenue in fiscal 2025.
Is ABCL profitable?
AbCellera Biologics Inc. (ABCL) reported -$146,412,000.00 of net income, with a net margin of -194.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.